Large-scale testing (Phase 3)Ended earlyNCT05870748
What this trial is testing
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Who this might be right for
Ovarian CancerEpithelial Ovarian CancerFallopian Tube Cancer+2 more
Sutro Biopharma, Inc. 600